

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Under the heading of 'Equality' the following 2 consultee comments were received:

1. *'Preferably prescribed by haematologists with an interest in managing patients with immune thrombocytopenic purpura'*
2. *'Patients unfit for surgery, who have received rituximab and intravenous immunoglobulin are a group of patients where understanding the clinical and cost effectiveness of this treatment is considered to be a priority.'*

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

None of the above 2 issues are considered an equality issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)

Issue date: June 2012

n/a

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

no

Approved by Associate Director (name): Elisabeth George

Date: 14 06 2012